PMID- 29045169
OWN - NLM
STAT- MEDLINE
DCOM- 20180427
LR  - 20181202
IS  - 1557-7732 (Electronic)
IS  - 1080-7683 (Linking)
VI  - 33
IP  - 9
DP  - 2017 Nov
TI  - Use of Topical Cannabinomimetic Palmitoylethanolamide in Ocular Surface Disease
      Associated with Antiglaucoma Medications.
PG  - 670-677
LID - 10.1089/jop.2016.0117 [doi]
AB  - PURPOSE: Chronic use of topical hypotensive therapies in glaucoma patients leads 
      to chronic inflammation of the ocular surface, which decreases the success rate
      of long-term glaucoma management. The aim of this study is to evaluate the effect
      of topical palmitoylethanolamide (PEA) (Defluxa((c))), a well-known
      anti-inflammatory and analgesic agent, in suppressing the ocular surface
      inflammation associated with the use of hypotensive eye drops. METHODS: In a
      pilot clinical trial, we enrolled 15 glaucomatous patients who received topical
      PEA (Defluxa) in addition to the current antiglaucoma drugs, while 15
      glaucomatous patients did not receive any additional treatment. At 3 different
      time points (day 0, 15, and 30), signs of ocular surface involvement, adverse
      events, visual acuity, and intraocular pressure were assessed. RESULTS: Topical
      PEA (Defluxa) was effective in increasing the Schirmer test (P < 0.05) and the
      tear film breakup time (T-BUT) (P < 0.0001), and improving the conjunctival
      hyperemia (P < 0.0001) by day 30, compared to baseline. Compared to control, by
      day 15, the conjunctival hyperemia score was significantly decreased in the PEA
      (Defluxa) group (P < 0.01), while the T-BUT and the Schirmer Test achieved a
      significant improvement by day 30 (P < 0.05; P < 0.01). DISCUSSION: Our data
      suggests that topical PEA (Defluxa) is a safe, effective, and generally
      well-tolerated treatment to prevent or suppress ocular surface inflammation
      attributable to chronic glaucoma treatment.
FAU - Di Zazzo, Antonio
AU  - Di Zazzo A
AD  - 1 IRCCS-Fondazione GB Bietti , Rome, Italy .
FAU - Roberti, Gloria
AU  - Roberti G
AD  - 1 IRCCS-Fondazione GB Bietti , Rome, Italy .
FAU - Mashaghi, Alireza
AU  - Mashaghi A
AD  - 2 Faculty of Mathematics and Natural Sciences, Leiden Academic Centre for Drug
      Research, Leiden University , Leiden, The Netherlands .
AD  - 3 Schepens Eye Research Institute , Massachusetts Eye and Ear Infirmary, Harvard 
      Medical School, Boston, Massachusetts.
AD  - 4 Basir Eye Health Research Center , Tehran, Iran .
FAU - Abud, Tulio Batista
AU  - Abud TB
AD  - 5 Department of Ophthalmology, Federal University of Sao Paulo, Sao Paulo, Brazil
      .
FAU - Pavese, Daniela
AU  - Pavese D
AD  - 6 Department of Ophthalmology, Campus Bio-Medico University, Rome, Italy .
FAU - Bonini, Stefano
AU  - Bonini S
AD  - 6 Department of Ophthalmology, Campus Bio-Medico University, Rome, Italy .
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Ocul Pharmacol Ther
JT  - Journal of ocular pharmacology and therapeutics : the official journal of the
      Association for Ocular Pharmacology and Therapeutics
JID - 9511091
RN  - 0 (Analgesics)
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Antihypertensive Agents)
RN  - 0 (Ethanolamines)
RN  - 0 (Ophthalmic Solutions)
RN  - 0 (Palmitic Acids)
RN  - 6R8T1UDM3V (palmidrol)
SB  - IM
MH  - Administration, Ophthalmic
MH  - Aged
MH  - Analgesics/administration & dosage/*therapeutic use
MH  - Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/*therapeutic use
MH  - Antihypertensive Agents/*adverse effects
MH  - Conjunctival Diseases/chemically induced/*drug therapy/metabolism
MH  - Ethanolamines/administration & dosage/*therapeutic use
MH  - Female
MH  - Glaucoma/*drug therapy
MH  - Humans
MH  - Hyperemia/chemically induced/*drug therapy/metabolism
MH  - Intraocular Pressure/drug effects
MH  - Male
MH  - Ophthalmic Solutions
MH  - Palmitic Acids/administration & dosage/*therapeutic use
MH  - Prospective Studies
MH  - Single-Blind Method
MH  - Tears/metabolism
MH  - Visual Acuity/drug effects
OTO - NOTNLM
OT  - *antiglaucoma drugs
OT  - *dry eye
OT  - *glaucoma
OT  - *inflammation
OT  - *ocular surface
OT  - *palmitoylethanolamide
EDAT- 2017/10/19 06:00
MHDA- 2018/04/28 06:00
CRDT- 2017/10/19 06:00
PHST- 2017/10/19 06:00 [entrez]
PHST- 2017/10/19 06:00 [pubmed]
PHST- 2018/04/28 06:00 [medline]
AID - 10.1089/jop.2016.0117 [doi]
PST - ppublish
SO  - J Ocul Pharmacol Ther. 2017 Nov;33(9):670-677. doi: 10.1089/jop.2016.0117.